论文部分内容阅读
目的 观察MVP与MEP方案对晚期非小细胞肺癌的近期疗效和毒性反应。方法 72例Ⅲb～Ⅳ期非小细胞肺癌 (NSCLC)随机分成MVP、MEP组 ,每组各 36例。MVP组用药MMC 8mg/m2 ivd1,VDS 3mg/m2 ,ivd1、8,DDP 5 0mgivgttd1～ 3;MEP组MMC、DDP用法同上 ,VP - 16 0 .1givgttd1～ 5,每疗程均为 2 1～ 2 8d。每组均完成 2个疗程以上化疗。结果 MVP组CR 3例 ,PR 14例 ,有效率 4 7.2 % (17/ 36 ) ;MEP组CR 0例 ,PR 14例 ,有效率为 38.9% (14 / 36 )。毒性反应主要为骨髓抑制 ,MVP组为 2 2 .2 % ,MEP组为 2 7.7% ,两组无显著性差异。MVP组有静脉炎及周围神经炎、腹痛 ,病人均可耐受。全部病例无肝、肾功能损害。结论 MVP方案与MEP方案疗效相似 ,MVP方案稍优于MEP方案。毒性反应可以耐受。两者均可作为治疗晚期NSCLC的一线方案
Objective To observe the short-term efficacy and toxicity of MVP and MEP regimens for advanced non-small cell lung cancer. Methods Seventy-two patients with stage IIIb-IV non-small cell lung cancer (NSCLC) were randomly divided into MVP and MEP groups, with 36 cases in each group. MVP group MMC 8mg/m2 ivd1, VDS 3mg/m2, ivd1, 8, DDP 50mgivgttd1 ~ 3; MEP group MMC, DDP usage ibid, VP - 16 0 .1givgttd1 ~ 5, each course is 2 1 ~ 2 8d . Each group completed more than 2 courses of chemotherapy. Results There were 3 cases of CR in the MVP group and 14 cases of PR with an effective rate of 4 7.2% (17/36). There were 0 cases of CR in the MEP group and 14 cases of PR. The effective rate was 38.9% (14/36). The main toxicity was myelosuppression, which was 22.2% in MVP group and 27.7% in MEP group. There was no significant difference between the two groups. The MVP group had phlebitis, peripheral neuritis, abdominal pain, and the patient could tolerate it. All cases had no liver and kidney damage. Conclusion The MVP regimen is similar to the MEP regimen in that the MVP regimen is slightly better than the MEP regimen. Toxicity can be tolerated. Both can be used as the first-line treatment for advanced NSCLC